Skip to content

MoonLake Immunotherapeutics MLTX Lease Liability Payments - Due Year Two

Lease Liability Payments - Due Year Two at other companies

Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$397K+4.5%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$18.11M+10.1%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
$2.88M+24.1%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Operating income-$70.0M-47.5%
Net income-$69.7M-74.5%
EPS (diluted)-$0.98-55.6%

Balance sheet

See full
Cash & equivalents$298.5M+9.9%
Total debt$100.8M+33.3%
Total equity$254.0M-37.7%
Total assets$400.4M-21.7%

Cash flow

See full
Operating cash flow-$66.3M-73.8%
CapEx--100%
Free cash flow-$66.3M-73.6%

Valuation

See full
Market cap$1.49B-45.9%
Enterprise value$1.29B-50.0%

Returns & leverage

See full
Return on equity-77.7%-221pp
Debt / equity0.4×+0.2×
Current ratio8.6×-12.5×

Where this comes from

Reported directly by MoonLake Immunotherapeutics in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo.

The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about MoonLake Immunotherapeutics's lease liability payments - due year two.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MoonLake Immunotherapeutics's lease liability payments - due year two?
MoonLake Immunotherapeutics (MLTX) reported lease liability payments - due year two of $458K in Q1 2026.
How has MoonLake Immunotherapeutics's lease liability payments - due year two changed year-over-year?
MoonLake Immunotherapeutics's lease liability payments - due year two increased by 236.8% year-over-year, from $136K to $458K.
What does lease liability payments - due year two mean?
This metric identifies the total cash payments required for operating and finance leases in the second year following the current balance sheet date. It helps investors forecast long-term fixed cost commitments and cash flow requirements. It is essential for modeling the company's future solvency and operational leverage.